This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any supplement or therapy.
What Is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It exists in two forms: NAD+ (oxidized) and NADH (reduced), and this redox pair is essential for cellular energy metabolism, DNA repair, gene expression regulation, and cellular signaling. While technically a dinucleotide rather than a peptide, NAD+ has become central to the longevity research community due to its fundamental role in the biology of aging.
NAD+ was first discovered in 1906 by Arthur Harden and William Young. However, it was the discovery of its role in activating sirtuins — a family of longevity-associated enzymes — in the early 2000s that catapulted NAD+ into the anti-aging spotlight. Research by David Sinclair at Harvard and others has positioned NAD+ decline as a hallmark of aging that may be therapeutically addressable.
Why NAD+ Declines with Age
NAD+ levels decrease substantially with age — by approximately 50% between the ages of 40 and 60 in some tissue measurements. This decline is driven by multiple factors:
- Increased CD38 activity: CD38, an enzyme that consumes NAD+, increases with age and chronic inflammation. It is now considered the primary driver of age-related NAD+ decline.
- PARP activation: DNA damage accumulates with age, activating poly(ADP-ribose) polymerase (PARP) enzymes that consume large quantities of NAD+ during DNA repair processes.
- Reduced biosynthesis: The efficiency of NAD+ biosynthetic pathways — particularly the salvage pathway enzyme NAMPT — decreases with age.
- Inflammation: Chronic low-grade inflammation ("inflammaging") upregulates NAD+-consuming enzymes while suppressing biosynthesis.
NAD+ and the Sirtuin Connection
Sirtuins (SIRT1-7) are NAD+-dependent deacetylase enzymes that regulate metabolism, inflammation, DNA repair, and stress resistance. They require NAD+ as a co-substrate — without adequate NAD+, sirtuin activity declines. SIRT1, the most studied family member, regulates mitochondrial biogenesis, fat metabolism, insulin sensitivity, and inflammatory pathways. SIRT3 governs mitochondrial function, while SIRT6 is critical for DNA repair and genomic stability.
The hypothesis driving much of NAD+ research is straightforward: restoring youthful NAD+ levels could reactivate sirtuin-mediated protective pathways that decline with age. Animal studies have supported this — NAD+ repletion in aged mice improved mitochondrial function, exercise capacity, insulin sensitivity, and various aging biomarkers.
Methods of NAD+ Restoration
Several strategies exist for raising NAD+ levels:
- NMN (nicotinamide mononucleotide): A direct NAD+ precursor that has shown efficacy in animal studies for raising tissue NAD+ levels. The landmark METRO trial and subsequent human studies have confirmed that oral NMN increases blood NAD+ levels, though clinical endpoints in humans are still being evaluated.
- NR (nicotinamide riboside): Another NAD+ precursor with established oral bioavailability. Multiple human trials have demonstrated it raises blood NAD+ by 40-90%. The CHROMAVIR trial showed NR increased NAD+ and improved markers of cellular health in older adults.
- IV NAD+: Direct intravenous infusion of NAD+ bypasses oral bioavailability limitations. Clinical protocols typically deliver 250-1000 mg over 2-4 hours. This approach is popular in longevity clinics but lacks large-scale efficacy trials.
- CD38 inhibition: Compounds like apigenin and quercetin may slow NAD+ consumption by inhibiting CD38, representing a complementary strategy to precursor supplementation.
Current Evidence and Limitations
The animal evidence for NAD+ repletion is robust — dozens of studies in mice show improvements in aging biomarkers, metabolic function, and even lifespan in some models. Human evidence is growing but more preliminary. NMN and NR reliably raise blood NAD+ levels, but whether this translates to the dramatic tissue-level benefits seen in mice is still under active investigation. Long-term safety data in humans is limited, and optimal dosing strategies remain debated.
The Bottom Line
NAD+ sits at the nexus of cellular energy production, DNA repair, and the sirtuin longevity pathways. Its age-related decline is well-documented and biologically significant. While the scientific rationale for NAD+ repletion is compelling and animal data is strong, translating these findings to confirmed human clinical benefits is an ongoing process. NAD+ precursors are available as supplements, while IV NAD+ is offered in clinical settings — but neither approach has received FDA approval for anti-aging indications.